Elucidating the mechanisms of action of new chemical entities and repurposed drugs against SARS-CoV-2

Project 9 Jul 2021
7

Laura Jeffreys

Director Catalyst Fund Award 2021

 

The SARS-CoV-2 pandemic has highlighted the need for drug strategies to treat emerging viral threats. This project focuses on elucidating the mechanisms of action (MoA) of several promising drugs, including the repurposed drug ivermectin and a new chemical series generated by collaborators. This work will identify druggable targets to aid in the design of novel chemotypes providing a career-enhancing and commercially-attractive IP opportunity for panviral therapies addressing an urgent global need. On completion, it is anticipated the outputs of this project will form the basis of future external fellowships and grants focusing on COVID-19 and other positive-sense RNA viral diseases.